About AZILECT(R)
AZILECT(R) (rasagiline tablets) is indicated for the treatment of the
signs and symptoms of Parkinson's disease both as initial therapy alone and
to be added to levodopa later in the disease. The effectiveness of AZILECT
was shown in patients with early PD who were receiving AZILECT as initial
therapy alone and who were not receiving any other PD therapy. The
effectiveness of AZILECT as adjunct therapy was shown in patients with PD
who were treated with levodopa.
Important Safety Information:
-- Patients should not take AZILECT if they are currently taking
meperidine as it could possibly result in a serious reaction such as
coma or death.
-- Patients should not take AZILECT with tramadol, methadone,
propoxyphene, dextromethorphan, St. John's wort, mirtazapine, or
cyclobenzaprine.
-- Patients should not take AZILECT with other monoamine oxidase
inhibitors (MAOIs), amphetamines, cold remedies containing
decongestants and weight-reducing preparations containing
pseudoephedrine, phenylephrine, phenylpropanolamine, or ephedrine in
order to avoid a possibly dangerous increase in blood pressure.
Symptoms of this reaction include severe headache, blurred vision,
difficulty thinking, seizures, chest pain, unexplained nausea or
vomiting, or signs or symptoms of a stroke. Patients or caregivers
should seek immediate medical attention if these symptoms or other
unusual symptoms occur.
-- In order to prevent a possibly dangerous increase in blood pressure,
patients taking AZILECT should avoid foods and beverages high in
tyramine content such as aged cheeses, air-dried meats, pickled
herring, yeast extract, aged red wines, tap/draft beers, sauerkraut,
and soy sauce.
-- Patients taking A
'/>"/>
| SOURCE Teva Neuroscience, Inc. Copyright©2008 PR Newswire. All rights reserved |